Similarly, another study found that the administration of a GRP94 and Her2/neu DNA vaccine to HER2+ breast cancer-bearing mice led to an increased immune response against the tumors evidenced by increased IFN-γ/IL-4 levels and decreased Tregs at the tumor site (97). This evidence concerns the gene ERBB2 and neoplasm.